



THE
FRONT
ROW
at Scripps Research



A Century
of Science
Changing Life



Making science matter: A vision for a new century of life-changing science

Peter Schultz, PhD

President and CEO, Scripps Research
L.S. "Sam" Skaggs Presidential Chair

ABOUT THE LECTURE

In 2024, Scripps Research is celebrating a century of scientific discovery and innovative medicines. In his lecture, President and CEO Peter Schultz shared examples of the Institute's key milestones spanning the last 100 years, highlighting its storied past as well as current accomplishments. As Scripps Research charts its course into the next century, Schultz discussed his vision for reinventing the nonprofit research institute model and expand the global impact on science, medicine and the public.

TOP TAKEAWAY POINTS

1. Over the last century, Scripps Research has made tremendous scientific strides in everything from revealing the secrets of our sensory and immune systems to creating new technologies to accelerate the discovery of life-saving medicines. The Institute now houses six research departments, multiple Nobel laureates and a top-ranked graduate school.
2. Scripps Research sets the standard for excellence in a number of research fields, evidenced by the steady stream of groundbreaking discoveries that emerge from the Institute's labs in chemistry, neuroscience, integrative structural and computational biology, molecular medicine, and immunology and microbiology, to name a few. Scripps Research discoveries have enabled 15 FDA-approved medicines.
3. Despite the remarkable advances in our understanding of human biology and disease, there is still an overwhelming need for new medicines, including for viral diseases, cancer and degenerative diseases of aging. One of the main barriers is that scientific discoveries and new insights into disease processes continue to be primarily made in academic research centers, while drug discovery and development are carried out in the biopharmaceutical industry.
4. To overcome these hurdles, Schultz is creating unique translational capabilities at Scripps Research in the form of the Calibr-Skaggs Institute for Innovative Medicines and the Scripps Research Translational Institute that seamlessly turn new discoveries into innovative, new medicines and clinical advances that impact human health. Already, Calibr-Skaggs has entered nine medicines into clinical trials, with many more in the pipeline.
5. As Scripps Research enters a new century, the Institute is pioneering the development of a new vision for research institutes which transcends conventional boundaries that constrain the impact on science, medicine and the public. This will help enable exceptional scientists to perform transformative research, while accelerating the advancement of new medicines for people around the world.